T Cell News and Research

Latest T Cell News and Research

Neurogenesis may encourage excessive weight gain and fat storage

New nerve cells formed in a select part of the brain could hold considerable sway over how much you eat and consequently weigh, new animal research by Johns Hopkins scientists suggests in a study published in the May issue of Nature Neuroscience.

21 May 2012

New optical microscope sees individual blood cells as they flow inside the body

Blood tests convey vital medical information, but the sight of a needle often causes anxiety and results take time. A new device developed by a team of researchers in Israel, however, can reveal much the same information as traditional blood test in real-time, simply by shining a light through the skin.

21 May 2012

TTFields therapy vs. chemotherapy in patients with recurrent glioblastoma

Results of the first randomized controlled trial to compare a novel cancer treatment modality delivering Tumor Treating Fields (TTFields) therapy versus chemotherapy in patients with recurrent glioblastoma (GBM) were published in the European Journal of Cancer.

21 May 2012

Scientists decipher structure of bacterial injection needles at atomic resolution

The plague, bacterial dysentery, and cholera have one thing in common: These dangerous diseases are caused by bacteria which infect their host using a sophisticated injection apparatus. Through needle-like structures, they release molecular agents into their host cell, thereby evading the immune response.

21 May 2012

Deletion of 'lunatic fringe' promotes tumor formation of basal-like breast cancers

Multiple research projects - including a 2006 study conducted at the University of North Carolina at Chapel Hill - have used DNA microarray analysis to identify several breast cancer subtypes, including luminal A, luminal B, basal-like and HER2-enriched.

21 May 2012

Regenerative medicine researchers explore innovative ways to treat childhood conditions

About 3 percent of the babies born in the United States have a birth defect. Children without a birth defect are also susceptible to injury or disease. At The University of Texas Health Science Center at Houston (UTHealth), regenerative medicine researchers are exploring innovative ways to treat these conditions.

21 May 2012

Growth promoting substance in human mesenchymal stem cells spurs restoration of nerves

A substance in human mesenchymal stem cells that promotes growth appears to spur restoration of nerves and their function in rodent models of multiple sclerosis (MS), researchers at Case Western Reserve University School of Medicine have found.

21 May 2012

HS6ST2 enzyme an important regulator of breast cancer cell-bone interactions

Researchers from VTT Technical Research Centre of Finland have in collaboration with the University of Turku, Indiana University and two Finnish companies, Biotie Therapies Corp. and Pharmatest Services Ltd, discovered a novel mechanism regulating the development of breast cancer bone metastases and showed that heparin-like compounds can potentially be used to inhibit breast cancer metastasis to bone.

21 May 2012

Cellectis launches human iPS derived hepatocyte product

Cellectis stem cells, a Business Unit of Cellectis Group, a premier provider of stem cell derived products and technologies, today announces the launch of a human iPS derived hepatocyte product, hiPS-HEP.

21 May 2012

Cobiprostone shows promise against NSAID-induced gastric mucosal injury

Sucampo Pharmaceuticals, Inc. today announced the presentation of preclinical data at Digestive Disease Week 2012, in San Diego, which demonstrates the protective effect of cobiprostone against epithelial barrier dysfunction in models of non-steroidal anti-inflammatory drug (NSAID)-induced gastric mucosal injury.

21 May 2012

Vaccination studies from Mercer University to be unveiled at AAPS’ NBC

Vaccination studies from Mercer University (Ga.) headline the groundbreaking research being unveiled at the American Association of Pharmaceutical Scientists' (AAPS) National Biotechnology Conference.

21 May 2012

Study uncovers distinct subtype of prostate cancer

A collaborative expedition into the deep genetics of prostate cancer has uncovered a distinct subtype of the disease, one that appears to account for up to 15 percent of all cases, say researchers at Weill Cornell Medical College, the Broad Institute of MIT and Harvard and the Dana-Farber Cancer Institute.

21 May 2012

Study identifies biomarkers that predict patients' response to certain colon cancer drugs

The Stem Cells and Cancer Research Group headed by Dr H-ctor G. Palmer at the Vall d'Hebr-n Institute of Oncology (VHIO) has identified the molecular mechanisms that determine patients' response to certain drugs used in clinical trials for colon cancer treatment. The study led by VHIO also benefited from the collaboration with Professor Alberto Mu-oz-s laboratory at the Instituto de Investigaciones Biomedicas Alberto Sols, Consejo Superior de Investigaciones Cient-ficas.

21 May 2012

Panobinostat able to target and destroy triple negative breast cancer

The histone de-acetylase (HDAC) inhibitor panobinostat is able to target and destroy triple negative breast cancer, reveals a new study published in BioMed Central's open access journal Breast Cancer Research.

21 May 2012

Scientists show positive results with human MSCs in animal models of MS

The Myelin Repair Foundation (MRF) today announced the results of a new peer-reviewed research study published in Nature Neuroscience that demonstrates functional improvement in immune response modulation and myelin repair with factors derived from mesenchymal stem cell (MSC) treatment in animal models of multiple sclerosis.

21 May 2012

Study uncovers mechanism by which Notch pathway could contribute to RA

A new study led by researchers at Hospital for Special Surgery identifies the mechanism by which a cell signaling pathway contributes to the development of rheumatoid arthritis (RA). In addition, the study provides evidence that drugs under development for diseases such as cancer could potentially be used to treat RA.

21 May 2012

Ceregene announces new data from CERE-120 clinical trial on Parkinson's

Ceregene Inc., a biotechnology company developing treatments for neurodegenerative diseases such as Parkinson's disease, will present new data demonstrating long-term, biologically-active expression of neurturin, a nervous system growth factor delivered to the degenerating dopamine nerves in patients with Parkinson's disease following treatment with CERE-120.

19 May 2012

Clinical data from Boston Scientific endoscopy studies to be presented at DDW

Boston Scientific Corporation announces that seven abstracts and additional clinical data analyses will be presented at Digestive Disease Week (DDW), May 19 – 22 in San Diego.

19 May 2012

Placental stem cells with key therapeutic properties can be harvested from chorion

Scientists at Children's Hospital Oakland Research Institute (CHORI) led by Vladimir Serikov, MD, PhD, and Frans Kuypers, PhD, report in the current Epub issue of Stem Cells Translational Medicine that placental stem cells with important therapeutic properties can be harvested in large quantities from the fetal side of human term placentas.

19 May 2012

Final results from C3BS-CQR-1 Phase II trial on heart failure

The Belgian biotechnology company, Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiovascular diseases, today announces that the final results of its Phase II clinical trial of C3BS-CQR-1 is will be presented at the late breaking clinical trial session at the European Society of Cardiology 2012 Heart Failure Congress in Belgrade, Serbia taking place on May 19-22.

19 May 2012